Abu Dhabi, June 25, 2025 – Marking a major milestone in global health innovation, the UAE has successfully launched its first diabetes-focused research mission into space. Part of the Axiom Mission 4 (Ax-4), this groundbreaking initiative took off from the Kennedy Space Center after several delays, aiming to redefine space health protocols for individuals with insulin-dependent diabetes mellitus (IDDM).

The flagship study, Suite Ride, is a joint effort between Abu Dhabi-based Burjeel Holdings and Axiom Space. It explores the viability of Continuous Glucose Monitors (CGMs) and insulin stability in microgravity, with the broader aim of making space travel accessible for astronauts with IDDM. Historically, this condition was deemed a barrier to spaceflight.

During the 14-day mission aboard the International Space Station (ISS), the four-member international crew—led by NASA astronaut Peggy Whitson—will conduct over 60 experiments from 31 countries. The Suite Ride project will provide real-time CGM data in space, overseen by Dr. Mohammad Fityan of Burjeel Medical City, in collaboration with Axiom’s scientific team. Their findings could revolutionize remote healthcare and diabetic treatment in hard-to-reach areas globally, especially across the MENA region.

Burjeel Medical City is also showcasing this achievement through a dedicated exhibition on space health, celebrating the UAE's role in advancing medical frontiers. With diabetes projected to impact 783 million people by 2045—an 87% rise in MENA alone—this mission represents hope for millions through innovation, inclusivity, and scientific excellence.